SCHEMBL247952

SCHEMBL247952

CC(C)(C1=N[C@H](C(C)(C)C)CO1)C1=N[C@H](C(C)(C)C)CO1

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL918052 1.00 CNR2 (0.31) CNR2
SCHEMBL3742324 1.00 CNR2 (0.31) CNR2
SCHEMBL31069784 1.00 CNR2 (0.31) CNR2
SCHEMBL1130554 1.00 CNR2 (0.31) CNR2
SCHEMBL2549969 0.90 ADRA2A (0.32)
SCHEMBL10227022 0.86 CNR2 (0.31) CNR2
SCHEMBL25860783 0.86
SCHEMBL17421987 0.83 CNR2 (0.30) CNR2
SCHEMBL12172138 0.79 CNR2 (0.32) CNR2
SCHEMBL22343067 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111057080-B Preparation method of boron-containing indolinone derivative 浙江工业大学 2022-07-08 CN claimed
EP-2855419-B1 NEW INDANYLOXYPHENYLCYCLOPROPANECARB OXYLIC ACIDS BOEHRINGER INGELHEIM INT (DE) 2017-03-01 EP claimed
JP-9255668-A None JP disclosed
US-20230331690-A1 THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF EYBNA TECHNOLOGIES LTD. (IL) 2023-10-19 US disclosed
EP-4237416-A1 THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF Bar Ilan University (IL) 2023-09-06 EP disclosed
CN-111057080-B Preparation method of boron-containing indolinone derivative 浙江工业大学 2022-07-08 CN disclosed
WO-2022091098-A1 THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF BAR-ILAN UNIVERSITY (IL) 2022-05-05 WO disclosed
CN-111057080-A Preparation method of boron-containing indolinone derivative 浙江工业大学 2020-04-24 CN disclosed
US-20160311791-A1 NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTOGONISTS FOR THE TREATMENT OF OSTEOPOSOSIS MERCK SHARP & DOHME CORP. (US) 2016-10-27 US disclosed
EP-3083621-A1 NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS Merck Sharp & Dohme Corp. (US) 2016-10-26 EP disclosed
WO-2015095261-A1 NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. (US) 2015-06-25 WO disclosed
EP-1054867-B1 ANTIVIRALS MEDIVIR AB (SE) 2004-04-14 EP disclosed
US-20040059138-A1 Dihydropyrancarboxamides and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2004-03-25 US disclosed
US-20030119881-A1 N-((2-hydroxy,3-(alkyloxo),6-halophenyl)-(1,2-cyclopropylene) -),N'-((5-cyano or bromo)pyrid-2-yl)urea; retroviricides; HIV reverse transcriptase inhibitors; prolonged time to virus resistance MEDIVIR AB (SE) 2003-06-26 US disclosed
US-6486183-B1 Antivirals MEDIVIR AB (SE) 2002-11-26 US disclosed
US-20020123645-A1 Method for producing optically active chrysanthemic acid SUMITOMO CHEMICAL COMPANY, LIMITED 2002-09-05 US disclosed
EP-1236708-A1 Method for producing optically active chrysanthemic acid SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-04 EP disclosed
EP-1054867-A1 ANTIVIRALS MEDIVIR AB (SE) 2000-11-29 EP disclosed
WO-1999036406-A1 ANTIVIRALS MEDIVIR AB (SE) 1999-07-22 WO disclosed
JP-H09255668-A PRODUCTION OF BISOXAZOLINES SUMITOMO CHEM CO LTD 1997-09-30 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331690-A1 THC DERIVATIVES, ORAL DOSAGE FORMS COMPRISING SAME, USES THEREOF FOR TREATING DISEASES AND DISORDERS AND SYNTHESIS THEREOF CNR2, CNR1, UGT1A10 CNR2 1/4885
US-20020123645-A1 Method for producing optically active chrysanthemic acid ENO1, CYP8B1, CRYAA CNR2 3828/4885
US-20040059138-A1 Dihydropyrancarboxamides and uses thereof CCNA1, DPYD, DHFR CNR2 182/4885
US-20160311791-A1 NOVEL TRICYCLIC CALCIUM SENSING RECEPTOR ANTOGONISTS FOR THE TREATMENT OF OSTEOPOSOSIS CASR, CALCR, CALCRL CNR2 145/4885
US-20030119881-A1 N-((2-hydroxy,3-(alkyloxo),6-halophenyl)-(1,2-cyclopropylene) -),N'-((5-cyano or bromo)pyrid-2-yl)urea; retroviricides; HIV reverse transcriptase inhibitors; prolonged time to virus resistance RAD1, POLL, PNPO CNR2 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.